• CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2

  • Back
22/09/2023 by   

Metadata

Document Title

CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2

Author

Laotee S., Duangkaew M., Jivapetthai A., Tharakhet K., Kaewpang P., Prompetchara E., Phumiamorn S., Sapsutthipas S., Trisiriwanich S., Somsaard T., Roytrakul S., Duangkhae P., Ongpipattanakul B., Limpikirati P., Pornputtapong N., Arunmanee W.

Affiliations

Department of Biochemistry and Microbiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand; Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center, Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Integrated Frontier Biotechnology for Emerging Disease, Chulalongkorn University, Bangkok, Thailand; Institute of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand; Functional Proteomics Technology Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology for Development Agency, Pathumthani, Thailand; Viral Vaccine Unit, Biologics Research Group, Research and Development Institute, The Government Pharmaceutical Organization, Bangkok, Thailand; Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand; Center of Excellence in Cancer Cell and Molecular Biology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand

Type

Article

Source Title

PLoS ONE

ISSN

19326203

Year

2023

Volume

18

Open Access

All Open Access, Gold

Publisher

Public Library of Science

DOI

10.1371/journal.pone.0288486

Format

PDF

Abstract

Subunit vaccines feature critical advantages over other vaccine platforms such as stability, price, and minimal adverse effects. To maximize immunological protection of subunit vaccines, adjuvants are considered as main components that are formulated within the subunit vaccine. They can modulate adverse effects and enhance immune outcomes. However, the most suitable formulation providing the best immunological outcomes and safety are still under investigation. In this report, we combined recombinant RBD with human IgG1 Fc to create an RBD dimer. This fusion protein was expressed in CHO and formulated with alternative adjuvants with different immune activation including Montanide ISA51, Poly (I:C), and MPLA/Quil-A? as potential vaccine candidate formulations. Using the murine model, a potent induction of anti-RBD IgG antibodies in immunized mice sera were observed. IgG subclass analyses (IgG1/IgG2a) illustrated that all adjuvanted formulations could stimulate both Th1 and Th2-type immune responses in particular Poly (I:C) and MPLA/Quil-A?, eliciting greater balance. In addition, Montanide ISA51-formulated RBD-Fc vaccination provided a promising level of neutralizing antibodies against live wild-type SARS-CoV-2 in vitro followed by Poly (I:C) and MPLA/Quil-A?, respectively. Also, mice sera from adjuvanted formulations could strongly inhibit RBD:ACE2 interaction. This study offers immunogenicity profiles, forecasted safety based on Vaccine-associated enhanced disease (VAED) caused by Th1-skewed immunity, and neutralizing antibody analysis of candidates of RBD-Fc-based subunit vaccine formulations to obtain an alternative subunit vaccine formulation against SARS-CoV-2. ? 2023 Laotee et al.

License

CC BY

Rights

Authors

Publication Source

WOS

Continue browsing